Aragon Pharmaceuticals is a small-molecule drug discovery company focused on developing medicines for the treatment of hormonally-driven cancers
Aragon Pharmaceuticals is a small-molecule drug discovery company focused on developing medicines for the treatment of hormonally-driven cancers. The company's lead compound, ARN-509, is an antiandrogen undergoing a Phase I/II clinical trial in patients with progressive, advanced castration-resistant prostate cancer. In addition to ARN-509, Aragon is advancing several compounds designed to both block and destroy hormone receptors that drive tumor growth.